ASX Announcements

ASX Announcements

Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising.

Date Title  
05 June 2023 Mesoblast Director Appointed to Strategic Advisory Role
26 May 2023 MSB Reports Q3 Financial Results and Operational Highlights
26 May 2023 Third Quarter Results Presentation
26 May 2023 Third Quarter Financial Results on Form 6-K
24 May 2023 Mesoblast Third Quarter Financial Results Webcast
03 May 2023 Becoming a substantial holder
03 May 2023 Change in substantial holding
01 May 2023 Cleansing Notice
28 April 2023 Application for quotation of securities - MSB
28 April 2023 Quarterly Activities/Appendix 4C Cash Flow Report
26 April 2023 Reinstatement to Official Quotation
26 April 2023 Proposed issue of securities - MSB
26 April 2023 Mesoblast Completes Private Placement
24 April 2023 Voluntary Suspension
20 April 2023 Trading Halt
20 April 2023 Pause in Trading
22 March 2023 FDA Schedules GvHD Pre-License Manufacturing Inspection
15 March 2023 Appendix 3G and Appendix 3H
08 March 2023 FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
08 March 2023 Pause in Trading
03 March 2023 Prospectus for Warrants Related to Oaktree Facility
28 February 2023 DREAM HF Trial Published in JACC
28 February 2023 MSB Q2 Financial Results and Operational Highlights
28 February 2023 Second Quarter Results Presentation
28 February 2023 Half Yearly Report and Accounts
27 February 2023 Mesoblast Second Quarter Financial Results Webcast
17 February 2023 Remestemcel Clinical and Potency Studies Presented at Tandem
09 February 2023 FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
01 February 2023 Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
31 January 2023 Quarterly Activities/Appendix 4C Cash Flow Report
16 January 2023 Appendix 3G, Appendix 3H and Appendix 3Ys
10 January 2023 Biotech Showcase 2023 Presentation in San Francisco

Share Price :    as of Jun 10, 2023